Develops cell therapies for Duchenne muscular dystrophy.
Dec 2025Revenue $0.00/yrExpenses $108M/yr
No trendCash runway ≈ 2.1 years from Jun 2026
Figures by year
When will Capricor Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $108M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $108M | −$108M |
| Dec 2024 | $22.3M | $64.8M | −$42.6M |
| Dec 2023 | $25.2M | $49.3M | −$24.1M |
| Dec 2022 | $2.55M | $32.2M | −$29.7M |
| Dec 2021 | $245K | $21.2M | −$20.9M |
| Dec 2020 | $310K | $14.0M | −$13.7M |
| Dec 2019 | $1.01M | $8.74M | −$7.73M |
| Dec 2018 | $1.67M | $17.0M | −$15.3M |
| Dec 2017 | $2.67M | $15.5M | −$12.9M |
| Dec 2016 | $4.00M | $21.0M | −$17.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.